Brief Title
Biomarkers in Tissue Samples From Patients With Stage I or Stage III Endometrial Cancer
Official Title
Micro RNA's Associated With Lymph Node Metastasis in Endometrial Cancer
Brief Summary
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may
help doctors identify and learn more about biomarkers related to cancer.
PURPOSE: This research study is studying at biomarkers in tissue samples from patients with
stage I or stage III endometrial cancer.
Detailed Description
OBJECTIVES:
- To identify microRNA expression patterns associated with lymph node metastasis in
samples from patients with endometrial cancer.
OUTLINE: Banked tumor tissue specimens are analyzed for microRNA expression profiling by
microarray analysis and reverse transcriptase-PCR assays.
Study Type
Observational
Primary Outcome
Association between microRNA expression and lymph node metastasis
Condition
Endometrial Cancer
Intervention
RNA analysis
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Genetic
Estimated Enrollment
100
Start Date
May 2010
Primary Completion Date
June 2010
Eligibility Criteria
DISEASE CHARACTERISTICS:
- Histologically confirmed endometrioid endometrial cancer
- Stage IA, IB, IC, or IIIC disease
- Any grade
- Enrolled and evaluated on GOG-0210 Molecular Staging Study of Endometrial Cancer
- Consented to allow their specimens and clinical data to be collected and stored
for future research
- Underwent complete surgical staging, including the following:
- Hysterectomy
- Bilateral oophorectomy
- Washings as well as pelvic lymphadenectomy (sampling of four left and four right
pelvic lymph nodes)
- Para-aortic lymphadenectomy (sampling of one left and one right para-aortic lymph
node)
- Sufficient high-quality frozen primary tumor for testing with ≥ 75% tumor cellularity
and ≤ 10% necrosis
PATIENT CHARACTERISTICS:
- Not specified
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
Gender
Female
Ages
N/A - N/A
Accepts Healthy Volunteers
No
Contacts
David S. Miller, MD, ,
Administrative Informations
NCT ID
NCT01119573
Organization ID
CDR0000672415
Secondary IDs
GOG-8014
Study Sponsor
Gynecologic Oncology Group
Collaborators
National Cancer Institute (NCI)
Study Sponsor
David S. Miller, MD, Principal Investigator, Simmons Cancer Center
Verification Date
May 2010